MA48637A - Polythérapies pour le traitement du cancer - Google Patents

Polythérapies pour le traitement du cancer

Info

Publication number
MA48637A
MA48637A MA048637A MA48637A MA48637A MA 48637 A MA48637 A MA 48637A MA 048637 A MA048637 A MA 048637A MA 48637 A MA48637 A MA 48637A MA 48637 A MA48637 A MA 48637A
Authority
MA
Morocco
Prior art keywords
polytherapies
cancer
treatment
Prior art date
Application number
MA048637A
Other languages
English (en)
Inventor
Dmitri Bobilev
Bruce Dezube
Andrew R Ferguson
Peng Sun
Original Assignee
Merck Sharp & Dohme
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Tesaro Inc filed Critical Merck Sharp & Dohme
Publication of MA48637A publication Critical patent/MA48637A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K1/00—Housing animals; Equipment therefor
    • A01K1/01—Removal of dung or urine, e.g. from stables
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/20—Analysis of motion
    • G06T7/215—Motion-based segmentation
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
    • H01R13/46—Bases; Cases
    • H01R13/516—Means for holding or embracing insulating body, e.g. casing, hoods
MA048637A 2017-05-09 2018-05-09 Polythérapies pour le traitement du cancer MA48637A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762503879P 2017-05-09 2017-05-09
US201762508359P 2017-05-18 2017-05-18
US201762556255P 2017-09-08 2017-09-08
US201862634789P 2018-02-23 2018-02-23
US201862646332P 2018-03-21 2018-03-21
US201862648327P 2018-03-26 2018-03-26

Publications (1)

Publication Number Publication Date
MA48637A true MA48637A (fr) 2021-03-17

Family

ID=64105496

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048637A MA48637A (fr) 2017-05-09 2018-05-09 Polythérapies pour le traitement du cancer

Country Status (12)

Country Link
US (1) US20200289493A1 (fr)
EP (1) EP3621592A4 (fr)
JP (2) JP2020519621A (fr)
KR (1) KR20200018436A (fr)
CN (1) CN110831580A (fr)
AU (3) AU2018264992A1 (fr)
BR (1) BR112019023591A2 (fr)
CA (1) CA3063201A1 (fr)
MA (1) MA48637A (fr)
MX (1) MX2019013373A (fr)
TW (1) TW201906632A (fr)
WO (1) WO2018208968A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
EA201992177A1 (ru) 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
ES2926255T3 (es) 2017-04-24 2022-10-24 Tesaro Inc Métodos de fabricación de niraparib
JP2020520921A (ja) 2017-05-18 2020-07-16 テサロ， インコーポレイテッド 癌を処置する併用療法
TW201927304A (zh) 2017-09-26 2019-07-16 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
TW201938165A (zh) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN115068603A (zh) * 2021-03-12 2022-09-20 中山康方生物医药有限公司 含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途
WO2022271547A1 (fr) 2021-06-21 2022-12-29 Tesaro, Inc. Traitement combiné du cancer avec un inhibiteur de parp et une statine lipophile
WO2023159066A1 (fr) 2022-02-15 2023-08-24 Tesaro, Inc. Utilisation de niraparib pour le traitement du cancer du cerveau

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2011153383A1 (fr) * 2010-06-04 2011-12-08 Bipar Science, Inc. Procédés de traitement d'un cancer des ovaires récurrent et résistant au platine avec du 4-iodo-3-nitrobenzamide en combinaison avec un antimétabolite et un composé de platine.
ES2909899T3 (es) * 2013-12-09 2022-05-10 Inst Curie Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
JP6663350B2 (ja) * 2014-01-16 2020-03-11 クロヴィス・オンコロジー，インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
SI3102605T1 (sl) * 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
RU2016142476A (ru) * 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US10174113B2 (en) * 2015-04-28 2019-01-08 Bristol-Myers Squibb Company Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
US20170000885A1 (en) * 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CN114796501A (zh) * 2015-06-25 2022-07-29 免疫医疗公司 抗体与治疗剂的组合治疗癌症的方法
CN108348480A (zh) * 2015-08-20 2018-07-31 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用于癌症治疗的组合疗法
NZ749413A (en) * 2016-06-29 2023-05-26 Tesaro Inc Methods of treating ovarian cancer
CA3059468A1 (fr) * 2017-04-27 2018-11-01 Tesaro, Inc. Agents anticorps diriges contre la proteine codee par le gene d'activation des lymphocytes 3 (lag-3) et utilisations associees

Also Published As

Publication number Publication date
BR112019023591A2 (pt) 2020-05-26
WO2018208968A1 (fr) 2018-11-15
CA3063201A1 (fr) 2018-11-15
JP2023093603A (ja) 2023-07-04
JP2020519621A (ja) 2020-07-02
AU2018264992A1 (en) 2019-12-05
EP3621592A1 (fr) 2020-03-18
US20200289493A1 (en) 2020-09-17
TW201906632A (zh) 2019-02-16
EP3621592A4 (fr) 2021-03-17
MX2019013373A (es) 2020-08-03
CN110831580A (zh) 2020-02-21
AU2021218080B2 (en) 2023-12-14
AU2021218080A1 (en) 2021-09-09
AU2023274126A1 (en) 2024-02-01
KR20200018436A (ko) 2020-02-19

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA45563A (fr) Méthodes de traitement du cancer de l'ovaire
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA45429A (fr) Polythérapie pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA41555A (fr) Polythérapie pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA41123A (fr) Polythérapie pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
MA46361A (fr) Traitement du cancer de la prostate
MA47408A (fr) Traitement du cancer